Greater celandine (Chelidonium majus L.) for COVID-19: A twenty-case series.

Content Provider	Europe PMC
Author	Gardin, Nilo E. Braga, Anne Jacqueline
Abstract	In December 2019, an outbreak of coronavirus disease 2019 (COVID‐19) occurred in Wuhan, China, with a rapid increase in cases worldwide. Until now, among several drugs tested, none demonstrated sufficient efficacy for its etiological treatment. Greater celandine (Chelidonium majus L.) is a well‐known medicinal plant, traditionally indicated for digestive disorders and topically to remove warts. This study, performed at private offices in São Paulo and Aracaju (Brazil), describes 20 consecutive COVID‐19 outpatients treated with greater celandine and their clinical evolution. The patients, aged 14–71 years (median of 41 years), were treated with Chelidonium majus 10% mother tincture, 20–30 drops three times a day for 3–12 days (median of 5 days). Clinical features were assessed during the treatment and at least until 1 week after its end. These cases were considered mild, as most COVID‐19 cases. The symptoms were mainly fever, fatigue, cough, sore throat, coryza, anosmia, ageusia, and headache. Ten patients had comorbidities, such as hypertension, diabetes, and overweight. Complete or almost complete clinical improvement occurred within 1–9 days of treatment (median of 3 days). There were no adverse events. This casuistry, although small, may inspire other researchers to continue investigating Chelidonium majus as a healing treatment for COVID‐19.
Related Links	https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC8250801&blobtype=pdf
Page Count	7
ISSN	0951418X
Journal	Phytotherapy Research [Phytother Res]
Volume Number	35
DOI	10.1002/ptr.7085
PubMed Central reference number	PMC8250801
Issue Number	7
PubMed reference number	33778996
e-ISSN	10991573
Language	English
Publisher	John Wiley & Sons, Ltd.
Publisher Date	2021-03-28
Publisher Place	Chichester, UK
Access Restriction	Open
Rights License	This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency. © 2021 John Wiley & Sons Ltd.
Subject Keyword	case series Chelidonium majus COVID‐19 greater celandine phytotherapy
Content Type	Text
Resource Type	Article
Subject	Pharmacology